中英双方近日宣布，英国布里斯托大学孵化的AI生物科技公司CellVoyant成功筹集了760万英镑的种子资金。该公司致力于利用人工智能成像技术，帮助干细胞疗法开发商更高效地研发新疗法。本轮融资由Octopus Ventures领投，Horizons Ventures、Air Street Capital和Verve Ventures参投。
CellVoyant是一家专注于生物科技领域的初创公司，其核心业务是利用人工智能技术为干细胞疗法开发商提供高效的制造解决方案。此次融资将助力CellVoyant进一步扩大业务规模，推动干细胞疗法领域的发展。
随着人工智能技术的不断进步，生物科技行业正迎来新一轮的创新热潮。CellVoyant的崛起表明，人工智能在生物科技领域的应用前景广阔，有望为干细胞疗法开发商带来革命性的变革。
英文翻译：
News Title: AI Biotech Company CellVoyant Raises £7.6 Million in Seed Funding
Keywords: Artificial Intelligence, Biotechnology, Stem Cell Therapy
News Content:
CellVoyant, an AI-driven biotech startup incubated by the University of Bristol, has recently raised £7.6 million in seed funding. The company aims to use artificial intelligence imaging technology to help stem cell therapy developers manufacture new treatments more efficiently. The round was led by Octopus Ventures, with participation from Horizons Ventures, Air Street Capital, and Verve Ventures.
CellVoyant is a startup specializing in the biotech sector, focusing on providing high-efficient manufacturing solutions to stem cell therapy developers using artificial intelligence technology. The funding will enable CellVoyant to further expand its business scope and promote the development of the stem cell therapy field.
With the continuous advancement of artificial intelligence, the biotech industry is witnessing a new wave of innovation. The rise of CellVoyant demonstrates that AI has broad application prospects in the biotechnology field and could bring about revolutionary changes to stem cell therapy developers.
【来源】https://sifted.eu/articles/ai-biotech-cellvoyant-raise
Views: 1